scholarly journals Laparoscopic radical distal pancreatosplenectomy with celiac axis excision following neoadjuvant chemotherapy for locally advanced pancreatic cancer

2021 ◽  
Author(s):  
Yeon Su Kim ◽  
Ji Su Kim ◽  
Sung Hyun Kim ◽  
Ho Kyoung Hwang ◽  
Woo Jung Lee ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Celiac Axis ◽  
Locally Advanced Pancreatic Cancer ◽  
Distal Pancreatosplenectomy

Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer

2019 ◽  
Vol 24 (7) ◽  
pp. 1605-1611 ◽  
Author(s):  
Shohei Yoshiya ◽  
Kengo Fukuzawa ◽  
Shoichi Inokuchi ◽  
Yukiko Kosai-Fujimoto ◽  
Kensaku Sanefuji ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Distal Pancreatectomy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Celiac Axis ◽  
Locally Advanced Pancreatic Cancer ◽  
En Bloc

scholarly journals Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

Cancer ◽  
2011 ◽  
Vol 118 (12) ◽  
pp. 3026-3035 ◽  
Author(s):  
Nils D. Arvold ◽  
David P. Ryan ◽  
Andrzej Niemierko ◽  
Lawrence S. Blaszkowsky ◽  
Eunice L. Kwak ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
Long Term Outcomes

Resection of locally advanced pancreatic cancer after neoadjuvant chemotherapy with modified FOLFIRINOX: A prospective phase II study

Pancreatology ◽  
2013 ◽  
Vol 13 (3) ◽  
pp. S88-S89
Author(s):  
Nelide De Lio ◽  
Enrico Vasile ◽  
Mario Antonio Belluomini ◽  
Francesca Costa ◽  
Carla Cappelli ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
Prospective Phase

scholarly journals Pancreatoduodenectomy After Neoadjuvant Chemotherapy for Locally Advanced Pancreatic Cancer in the Presence of an Aberrant Right Hepatic Artery

In Vivo ◽  
2019 ◽  
Vol 34 (1) ◽  
pp. 401-406
Author(s):  
NICOLAE BACALBASA ◽  
IRINA BALESCU ◽  
MIHAELA VILCU ◽  
ADINA CROITORU ◽  
SIMONA DIMA ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Hepatic Artery ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
Right Hepatic Artery

scholarly journals Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000668 ◽  
Author(s):  
Vincent Picozzi ◽  
Adnan Alseidi ◽  
Jordan Winter ◽  
Michael Pishvaian ◽  
Kabir Mody ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Tissue Growth ◽  
Locally Advanced Pancreatic Cancer ◽  
Complication Rates ◽  
Surgical Exploration ◽  
Matrix Deposition

PurposePancreatic ductal adenocarcinomas exhibit a high degree of desmoplasia due to extensive extracellular matrix deposition. Encasement of mesenteric vessels by stroma in locally advanced pancreatic cancer (LAPC) prevents surgical resection. This study sought to determine if the addition of a monoclonal antibody to connective tissue growth factor, pamrevlumab, to neoadjuvant chemotherapy would be safe and lead to improved resectability in this surgically adverse patient population.MethodsIn this phase I/II trial, 37 patients with LAPC were randomised 2:1 to gemcitabine/nab-paclitaxel plus (Arm A, n=24) or minus (Arm B, n=13) pamrevlumab. Those who completed six cycles of treatment were assessed for surgical eligibility by protocol-defined criteria. Resection rates, progression-free and overall survival were evaluated.ResultsEighteen (75%) patients in Arm A and seven (54%) in Arm B completed six cycles of therapy with similar toxicity patterns. In Arms A and B, carbohydrate antigen 19–9 response, as defined by ≥50% decline from baseline, occurred in 13 (65%) and 5 (42%), respectively. Sixteen (16%) per cent of patients were radiographically downstaged by National Comprehensive Cancer Network criteria (5 in Arm A (21%) and 1 (8%) in Arm B). Positron emission tomography normalised in 9 (38%) vs 3 (23%) of patients in Arm A vs Arm B, respectively, and correlated with surgical exploration. Eligibility for surgical exploration was 17 (71%) vs 2 (15%) (p=0.0019) and resection was achieved in 8 (33%) vs 1 (8%) of patients in Arm A vs Arm B (p=0.1193), respectively. Postoperative complication rates were not different between arms.ConclusionsNeoadjuvant chemotherapy with pamrevlumab holds promise for enhancing resection rates in patients with LAPC without added toxicity. This combination merits evaluation in a larger patient cohort.

Sign in / Sign up

Export Citation Format

Share Document